Michèle Ollier

Michèle is a co-founder and Senior Advisor at Medicxi. Prior to Medicxi, Michèle was a Partner at Index Ventures for 10 years, having joined in 2006. Michèle currently serves on the board of Alys Pharmaceuticals. Investments led by Michèle include Villaris Therapeutics (acquired by Incyte Corporation), Kaerus Biosciences (acquired by Servier), OncoEthix (acquired by Merck), Minerva Neurosciences (NASDAQ:NERV), Pearl River Bio and Palladio Biosciences (both acquired by Centessa Pharmaceuticals) and Aegerion (NASDAQ:AEGR).

Prior to joining Index Ventures, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/ Gencell/ Aventis International and Serono International. 

Michèle currently serves on the board of directors of Ipsen Pharmaceuticals (Euronext:IPN).

Michèle completed her medical studies in France at Paris Ouest University.